Easing of Japanese Tarceva restrictions in NSCLC set to raise pressure on Iressa
This article was originally published in Scrip
Executive Summary
Japan's ministry of health, labour and welfare has lifted some of the post-marketing restrictions on Chugai/Roche/OSI's oral epidermal growth factor receptor inhibitor Tarceva (erlotinib), signalling its satisfaction with initial safety and efficacy data.